MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$8,197,565
EPS
-$4.35
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2025-10-31
2025-07-31
Research and development expenses
6,683,643
5,317,669.5*
General and administrative expenses
1,639,300
1,483,531.25*
Total operating expenses
8,322,943
6,801,200.75
Operating loss
-8,322,943
-6,801,200.75*
Financial income, net
158,646
28,627.75*
Change in fair value of the warrant liability
69,201
-189,591*
Share of loss on equity investment
-44,830
-56,053*
Net loss for the period
-8,278,328
-6,639,035*
Net loss attributable to non-controlling interest
-80,763
-61,068.25*
Net loss for the period attributable to briacell
-8,197,565
-6,577,966.75
Basic EPS
-4.35
-15.547
Diluted EPS
-4.35
-15.547
Basic Average Shares
1,883,906
423,114
Diluted Average Shares
1,883,906
423,114
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss for the
period attributable to...
-$8,197,565
Net loss
attributable to...
-$80,763
Net loss for the
period
-$8,278,328
Financial income, net
$158,646
Operating loss
-$8,322,943
Change in fair value of
the warrant...
$69,201
Share of loss on equity
investment
-$44,830
Total operating
expenses
$8,322,943
Research and development
expenses
$6,683,643
General and
administrative expenses
$1,639,300
Buy us a coffee
BriaCell Therapeutics Corp. (BCTXW)
BriaCell Therapeutics Corp. (BCTXW)